News

Drugmaker deploys NVIDIA DGX SuperPOD with Vera Rubin systems to accelerate medicine discovery.

Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index shedding 1.1% and t

The drugmaker will deploy NVIDIA's Vera Rubin systems, giving it what it calls the most powerful AI computing infrastructure in life sciences

The Dow Jones Industrial Average was down, while the S&P 500 and Nasdaq Composite were up, as chipma

Bristol Myers Squibb (NYSE:BMY) has expanded its artificial intelligence collaboration with Nvidia (NASDAQ:NVDA), announcing plans to deploy an Nvidia DGX SuperPOD powered by DGX Vera Rubin NVL72 systems to strengthen its AI infrastructure for drug discovery and development. The expansion builds on a partnership that began nearly three years ago and is designed to provide significantly greater computing power for AI-driven research.

For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies. Bispecific antibodies are being tested by Bristol Myers Squibb (with its partner BioNTech ), AstraZeneca and the biotech firm Summit Therapeutics ADCs have already rung up big sales for Astra, Pfizer Gilead Sciences and Roche Holding but Merck has a strong contender in development.

Bristol Myers Squibb said on Monday it is buying the latest-generation computing system from chip company Nvidia ‌to support its use of artificial intelligence across its drug discovery and development ‌operations. The drugmaker said it will be the first life sciences company to buy an Nvidia DGX SuperPOD ​based on its Vera Rubin systems. The chipmaker unveiled its Vera Rubin architecture earlier this year as the successor to its current generation of AI computing systems.

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.

For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies. Bispecific antibodies are being tested by Bristol Myers Squibb (with its partner BioNTech ), AstraZeneca and the biotech firm Summit Therapeutics ADCs have already rung up big sales for Astra, Pfizer Gilead Sciences and Roche Holding but Merck has a strong contender in development.

The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.

Bristol Myers Squibb (BMY) reached $60.48 at the closing of the latest trading day, reflecting a +2.99% change compared to its last close.

The pharma division is firing on all cylinders, but a sudden crack in the MedTech business has the market worried about the company's new two-part growth plan.

FDA has accepted Bristol Myers Squibb's New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. The filing is supported by a Phase 3 trial that showed a meaningful improvement in progression free survival for this patient group. This decision marks a key regulatory milestone for NYSE:BMY's oncology pipeline and could influence how investors view its future revenue mix. Bristol-Myers Squibb enters this news cycle...

Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

(Bloomberg) -- AdvanCell Pty, a biotechnology firm backed by Eli Lilly & Co., has raised $315 million in new funding, underscoring investor confidence in its experimental cancer therapy.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsTrump Drops 20% Fee for Hormuz Cargo After Gulf PressureUS Hits Iran With Strikes, Blockade as Trump Plans Hormuz ChargeOpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI Companion‘We Faltered’: IBM Plunges M

BMY's FDA filing for mezigdomide in relapsed or refractory multiple myeloma marks another step in advancing its protein degrader pipeline.

Drug pricing matters, but pipelines matter even more.

For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.

CYTK enters a new era after Myqorzos FDA approval, with early US uptake, European expansion and lifecycle studies fueling its commercial momentum.

Pfizer's (PFE) second-quarter revenue is expected to match Wall Street's estimates, while its earnin

Bristol-Myers Squibb (BMY) was recently removed from several Russell growth benchmarks and added to the Russell 1000 Defensive and Russell 1000 Value-Defensive indices, shifting how many institutional investors may gain exposure to the stock. See our latest analysis for Bristol-Myers Squibb. At a share price of US$57.54, Bristol-Myers Squibb has seen mixed short term moves, with the 7 day share price return of 1.95% and 30 day share price return of 3.55% contrasting with a 90 day decline of...

Prothena shares climb as late-stage partnered programs advance, milestone payments strengthen finances and its neurodegenerative pipeline continues to expand.

Get paid a guaranteed income now on your Amgen shares, which you keep no matter what, in exchange for agreeing to sell at a price that's already a win.

Bristol Myers Squibb (NYSE:BMY) Foundation’s QUILS initiative is reshaping lung cancer early detection in Kentucky. The program is now serving as a model for similar efforts in Mississippi and Nevada. QUILS targets earlier identification of lung cancer in regions with some of the highest reported rates in the country. Bristol Myers Squibb operates as a global biopharmaceutical company with a focus on oncology, immunology, and cardiovascular treatments. The QUILS initiative adds a public...

AbbVie's stock commands a king's ransom, but its performance metrics rule the kingdom, leaving investors to ask if they are buying at the top of the reign.

Bristol-Myers Squibb is expected to report its second-quarter earnings later this month, and Wall Street is calling for a double-digit decrease in profit.

In late June 2026, Janux Therapeutics, Inc. was removed from several Russell growth and small-cap benchmarks, including the Russell 2000 Growth, 2500 Growth, Small Cap Comp Growth, 3000E Growth, and 3000 Growth indexes. This broad index removal matters because it can force index-tracking funds to rebalance, potentially changing who holds the stock and how it trades. Next, we’ll examine how Janux’s removal from multiple Russell growth indexes shapes the company’s investment narrative for...